GlassScriptPhysician profile
Kerrie Lynn David
NPI 1760481469
$7,078.13
in general payments reported to CMS, 2019-2025
54 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $834 · 2021: $987 · 2022: $1,029 · 2023: $1,261 · 2024: $1,135 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $674.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $546.90 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $532.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $429.20 | 2019-2024 | |
| Lilly USA, LLC | $425.14 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $385.16 | 2020-2025 | |
| Organogenesis INC. | $347.33 | 2019-2024 | Puraply, Puraply Wound Matrix |
| Amarin Pharma, INC. | $326.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.28 | 2020-2025 | Jardiance, Ofev, Tradjenta |
| Smith+Nephew, INC. | $310.78 | 2019-2025 | Collagenase Santyl, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Astellas Pharma US INC | $192.39 | 2020-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $179.31 | 2019-2022 | |
| Corcept Therapeutics | $171.57 | 2024-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $163.04 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $162.14 | 2019-2023 | Xarelto |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerrie David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.